Immunosuppression by Mutated Calreticulin Released from Malignant Cells

G.K. and L. Zitvogel are supported by the Ligue Contre le Cancer (équipe labelisee); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la Recherche sur le Cancer (ARC); Cance´ ropole Ile-de-France; Chancelerie des universites de Paris (Legs Poix); Fondation pour la Recherche Medicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea; the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051); Institut National Du Cancer(INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumiere; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). I.P., C.M., and W.V. were funded by INCA PLBio 2015 and by the Ligue Contre le Cancer (equipe labelisee). F.P. is supported by the ANR, the Institut Curie, and the Centre National de la Recherche Scientifique (CNRS).